v3.25.3
Consolidated Shareholders' Equity - Additional Information (Details) - EUR (€)
 6 Months Ended 12 Months Ended
Apr. 30, 2025
Feb. 02, 2025
Jan. 29, 2025
Apr. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jan. 31, 2024
Disclosure of classes of share capital [Line Items]                
Share capital         € 2,455,512,548      
Number of shares (in shares)         1,227,756,274      
Par value per share (in euros per share)         € 2      
Number of restricted shares vested (in shares)         2,682,051      
Number of restricted shares alloted in regards of capital increase         1,525,846      
Other comprehensive income that will be reclassified to profit or loss, net of tax [1]         € (5,318,000,000) € 1,067,000,000 [2]    
Cancellation of treasury shares         3,868,000,000      
Employees share ownership plan                
Disclosure of classes of share capital [Line Items]                
Subscription price (in euros per share)     € 72.97         € 72.87
Number of shares subscribed (in shares)     2,260,776         2,124,445
Number of shares issued immediately for employer's contribution (in shares)     116,794         119,951
Expense recognized         € 31,000,000 45,000,000    
Share Repurchase 2024 Program                
Disclosure of classes of share capital [Line Items]                
Period of share repurchase program 18 months     18 months        
Number of shares repurchased (in shares)         39,344,633      
Amount of shares repurchased         € 3,988,000,000      
Share Repurchase 2025 Program                
Disclosure of classes of share capital [Line Items]                
Number of shares repurchased (in shares)         29,556,650      
Amount of shares repurchased   € 3,000,000,000 € 5,000,000,000          
Per Share Value of Shares Repurchased   € 101.5            
Share capital | Sanofi                
Disclosure of classes of share capital [Line Items]                
Capital increase by exercise of stock subscription options (in shares)         171,150      
Capital increase by issuance of restricted shares (in shares)         1,156,205      
Other comprehensive income | Items subsequently reclassifiable to profit or loss                
Disclosure of classes of share capital [Line Items]                
Other comprehensive income that will be reclassified to profit or loss, net of tax         € (5,017,000,000) € 1,067,000,000    
Other comprehensive income | Foreign Currency Translation | Items subsequently reclassifiable to profit or loss                
Disclosure of classes of share capital [Line Items]                
Other comprehensive income that will be reclassified to profit or loss, net of tax         459,000,000   € 5,000,000  
Other comprehensive income | Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures [Member] | Items subsequently reclassifiable to profit or loss                
Disclosure of classes of share capital [Line Items]                
Other comprehensive income that will be reclassified to profit or loss, net of tax         € 2,000,000      
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.